Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bictegravir/emtricitabine/tenofovir alafenamide versus abacavir/dolutegravir/lamivudine in treatment-naive adults with HIV-1
2015-004024-54Phase 3Unknown
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing bictegravir/emtricitabine/tenofovir alafenamide with abacavir/dolutegravir/lamivudine (2 arms). Primary endpoint: Proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48. Status: unknown.
02
Drugs
bictegraviremtricitabinetenofovir alafenamideabacavirdolutegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-004024-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004024-54.